Regulus Therapeutics Reports In-Line Q3 EPS

  • Investing.com
Regulus Therapeutics Reports In-Line Q3 EPS

Regulus Therapeutics (RGLS) reported Q3 EPS of ($0.50), in-line with the analyst estimate of ($0.50).

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100